USC Norris Comprehensive Cancer Center and Hospital /ID# 147543
Welcome,         Profile    Billing    Logout  
 3 Trials 
7 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wagle, Naveed
BETA-PRIME, NCT04673942: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Recruiting
2
140
US
AdAPT-001, Checkpoint Inhibitor, Immune
EpicentRx, Inc.
Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
12/25
03/27
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
IORT, NCT04681677: Recurrent GBM Treated With Neurosurgical Resection and Using the Xoft Axxent eBx System and Bevacizumab

Terminated
2
12
US
Radiation: Intra-operative Radiation Therapy - IORT, Bevacizumab, Avastin
Xoft, Inc., Icad, Inc.
Glioblastoma, Recurrent Glioblastoma, GBM, Recurrent GBM
04/24
04/24
NCT05561374: Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
16
US
Low-dose OKN-007, BID, Low-dose OKN-007, TID, Mid-dose OKN-007, TID, High-dose OKN-007, TID
Oblato, Inc.
High-grade Glioma, Oligodendroglioma, Astrocytoma, Glioblastoma Multiforme
05/25
06/25
NCT04901806 / 2021-001029-32: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Terminated
1
29
Europe, US, RoW
PBI-200
Pyramid Biosciences, Pyramid Biosciences, Inc., Pyramid Biosciences
Solid Tumor, Adult, Brain Tumor, Primary, Desmoplastic Small Round Cell Tumor
07/23
07/23
NCT04566393: Expanded Access to Ulixertinib (BVD-523) in Patients with Advanced MAPK Pathway-Altered Malignancies

Available
N/A
US
Ulixertinib (BVD-523)
xCures, Cancer Commons
Pancreatic Cancer, Small Bowel Cancer, Colorectal Cancer, Melanoma, Non Small Cell Lung Cancer, Thyroid Cancer, Bladder Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer, Cholangiocarcinoma, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, MAPK Gene Mutation, KRAS Activating Mutation, BRAF Gene Mutation, NRAS Gene Mutation, HRAS Gene Mutation, MEK Mutation, ERK Mutation
 
 
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26

Download Options